Indication
Mast Cell Leukemia
5 clinical trials
4 products
Product
midostaurinClinical trial
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesStatus: Completed, Estimated PCD: 2022-10-05
Clinical trial
GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic MastocytosisStatus: Terminated, Estimated PCD: 2021-08-02
Product
GTB-3550 TriKEProduct
AvapritinibProduct
bezuclastinibClinical trial
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisStatus: Active (not recruiting), Estimated PCD: 2026-01-31
Clinical trial
A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic MastocytosisStatus: Recruiting, Estimated PCD: 2025-01-01